<DOC>
	<DOC>NCT02200575</DOC>
	<brief_summary>Study to confirm the safety profile of telmisartan (benefit-risk ratio) under normal conditions of use after market launch and to supplement the present data on the safety of telmisartan. Furthermore to assess effectiveness of a single dose of telmisartan per day to control blood pressure for 24 hours, especially during the last few hours of the dosage interval. Additionally to evaluate compliance with treatment, as an indirect measurement, and to confirm the efficacy and possible risks associated with treatment.</brief_summary>
	<brief_title>Pharmacovigilance and Patient Compliance in Hypertensive Patients</brief_title>
	<detailed_description />
	<mesh_term>Telmisartan</mesh_term>
	<criteria>Patients of either sex over the age of 18 years suffering from nonsecondary essential hypertension with values of at least 90 mmHg (diastolic) and 140 mmHg (systolic) corresponding to the contraindications listed in the summary of product characteristics of the drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>